• Jiapeng Wang, Wang Lou, Yingnan Li, Yang Jiang, Xue Jiang, and Lin Yang.
• Department of Orthopedics, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China.
• Medicine (Baltimore). 2024 Nov 29; 103 (48): e40742e40742.

AbstractAnkylosing spondylitis (AS) is a chronic inflammatory disease characterized by axial osteoarticular inflammation and tendon enthesitis with unclear pathogenesis. Nonsteroidal anti-inflammatory drugs and antirheumatic drugs used in the traditional treatment of AS have some problems such as drug intolerance and inadequate treatment response. Since the introduction of biological agents in the treatment of AS, they have completely changed the treatment concept of AS, and because of their safety and good tolerance, they have become the main choice for clinical AS patients. This article systematically summarizes the current status of targeted therapy for AS worldwide, analyzes the advantages and disadvantages of different types of biological agents in the treatment of AS, and provides an objective evaluation of clinical targeted therapy for AS, in order to provide a new perspective for clinical standardized treatment.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

13 keywords...

hide…